华商甄选回报混合A（010761）成立日期2021年1月19日，最新规模27.28亿。今年以来收益49.23%，同 类排名1269/8085；近一年收益47.32%，同类排名1222/8085；成立以来收益116.28%。 华商甄选回报混合A（010761）基金经理为余懿、孙蔚、崔志鹏。 截至发稿，余懿累计任职时间3年111天，现任基金资产总规模82.29亿元，任职期间最佳基金回报 81.1%， 任职期间最差基金回报-4.02%。 孙蔚累计任职时间2年363天，现任基金资产总规模79.4亿元，任职期间最佳基金回报70.94%， 任职期 间最差基金回报-17.24%。 崔志鹏累计任职时间1年364天，现任基金资产总规模40.16亿元，任职期间最佳基金回报72.4%， 任职 期间最差基金回报-4.67%。 12月31日，润都股份涨1.08%，截至发稿，报12.15元/股，成交1618.82万元，换手率0.52%，总市值 40.69亿元。 资料显示，珠海润都制药股份有限公司位于广东省珠海市金湾区三灶镇机场北路6号，成立日期1999年 12月30日，上市日期2018年1月5日，公司主营业务涉及化学药制剂、化学原料药、 ...

齐鲁晚报·齐鲁壹点记者于军队采购网了解到，12月15日，上药控股（锦州）有限公司上榜军队采购失信名单，处理部门为海后采购和资产管理局。处罚 生效范围（单位）：全军；处罚生效范围（品种）：全品种。 据失信处理公告内容，上药控股（锦州）有限公司的具体违规情形为"围标串标"。违规情况显示，经调查核实，上药控股（锦州）有限公司在参加项目编 号2024-JH13-W1002采购活动中，存在围标串标等违规行为。其处理编号为SX2025124439，违规处理状态：处罚期限内。 处理部门根据军队供应商管理相关规定，作出禁止其在3年内参加全军物资工程服务采购活动的处罚。以上处理自2025年12月15日起算。在禁止期内，其 时任法定代表人袁克华控股或管理的其他企业禁止参加上述范围军队采购活动，授权代表王子铭禁止代理其他供应商参加上述范围军队采购活动。 据上药控股（锦州）有限公司官网介绍，现公司是集药品分销、营销服务、医疗器械于一体的大型医药商业企业。公司药品主要经营中成药、化学药制 剂、化学原料药、抗生素、生化药品、生物制品、第二类精神药品制剂、蛋白同化制剂、肽类激素，年销售额9000万元左右。 国家企业信用信息公示系统显示，上 ...

更公司 查老板 童关系 查风险 都 在 用 的 商 业 查 词 工 具 (× 云南白药集团股份有限公司 天眼一下 国家中小企业发展子基金旗下机构 基本信息 217 上市信息 999+ 法律诉讼 413 经营风险 81 经营信息 999+ 主要股东 2 ● 品股权结构 股权变更历程140 ? 最新公示3 工商登记5 历史主要股东2 序号 股份类型 股东名称 云南省国有股权运营管理有限公司 器 1 流通A股 大股东 | 圆 省管国企 新华都实业集团股份有限公司 品 2 流通A股 大股东 云南合和（集团）股份有限公司 器 3 流通A股 大股东 | 国有独资 每经AI快讯，天眼查工商信息显示，近日，云南白药（000538）发生工商变更，董明卸任法定代表人，王明辉卸任董事长，由张文学接任，注册资本由约 10.4亿元人民币增至约17.8亿元人民币，同时，多位高管发生变更。云南白药集团股份有限公司成立于1993年11月，经营范围含化学原料药、化学药制剂、 中成药、中药材、生物制品、医疗器械等的销售，信息技术、科技及经济技术咨询服务，货物进出口等。股东信息显示，该公司由云南省国有股权运营管理 有限公司、新华都（002264） ...

Core Viewpoint - Warner Pharmaceutical experienced a significant decline in stock price, dropping 6.60% on November 21, with a trading volume of 203 million yuan, indicating potential investor concerns and market volatility [1]. Financing Summary - On November 21, Warner Pharmaceutical had a financing buy amount of 31.43 million yuan and a financing repayment of 78.80 million yuan, resulting in a net financing outflow of 47.37 million yuan [1]. - The total financing and securities balance for Warner Pharmaceutical reached 310 million yuan, accounting for 5.19% of its market capitalization, which is above the 60th percentile level over the past year, indicating a relatively high financing level [1]. - No shares were sold or repaid in the securities lending market on November 21, with the securities lending balance also at zero, suggesting a lack of short-selling activity [1]. Company Performance - As of September 30, Warner Pharmaceutical reported a total of 6,416 shareholders, a decrease of 11.83% from the previous period, while the average circulating shares per person increased by 13.42% to 20,467 shares [2]. - For the period from January to September 2025, Warner Pharmaceutical achieved a revenue of 1.086 billion yuan, reflecting a year-on-year growth of 1.55%, and a net profit attributable to shareholders of 207 million yuan, which is a 30.75% increase year-on-year [2]. Dividend and Shareholding Information - Warner Pharmaceutical has distributed a total of 291 million yuan in dividends since its A-share listing, with 225 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, Anxin Medical Health Stock A held 1.2294 million shares, remaining unchanged, while China Europe Enjoy Life Mixed A entered the list as a new shareholder with 1.0891 million shares [3].

Group 1 - Warner Pharmaceutical's stock price dropped by 5% to 46.17 CNY per share, with a total market capitalization of 6.063 billion CNY, and has seen a cumulative decline of 7.07% over the past five days [1] - The company, established on April 30, 2001, specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations, with 73.19% of its revenue coming from formulations [1] - The stock has a trading volume of 70.8521 million CNY and a turnover rate of 1.15% [1] Group 2 - According to data, the fund "Zhaoshang Yutai Mixed" (016375) holds 77,900 shares of Warner Pharmaceutical, accounting for 3.6% of the fund's net value, making it the eighth largest holding [2] - The fund has incurred a floating loss of approximately 189,400 CNY today and a total floating loss of 288,400 CNY during the five-day decline [2] - The fund was established on December 16, 2022, with a current size of 124 million CNY and has achieved a year-to-date return of 10.18% [2] Group 3 - The fund manager of "Zhaoshang Yutai Mixed" is Li Gongmin, who has a tenure of 11 years and 83 days, with the fund's best return during his tenure being 28.83% and the worst being -30.41% [3]

Core Insights - Warner Pharmaceutical's stock price decreased by 0.67% on November 14, with a trading volume of 161 million yuan [1] - The company reported a net profit growth of 30.75% year-on-year for the first nine months of 2025, reaching 207 million yuan [2] Financing and Margin Trading - On November 14, Warner Pharmaceutical had a financing buy-in amount of 24.6 million yuan and a net buy of 3.35 million yuan, with a total financing balance of 353 million yuan, accounting for 5.17% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a high level of financing activity [1] Shareholder and Institutional Holdings - As of September 30, 2025, the number of shareholders decreased by 11.83% to 6,416, while the average circulating shares per person increased by 13.42% to 20,467 shares [2] - The company has distributed a total of 291 million yuan in dividends since its A-share listing, with 225 million yuan distributed over the past three years [3] Business Overview - Warner Pharmaceutical, established on April 30, 2001, specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - The revenue composition includes 73.19% from formulations, 25.22% from raw materials and intermediates, and 1.52% from technical services [1]

Core Viewpoint - Warner Pharmaceutical's stock increased by 5.06% to 61.43 CNY per share, with a total market capitalization of 8.067 billion CNY as of October 15 [1] Company Overview - Warner Pharmaceutical, established on April 30, 2001, is located in Changsha, Hunan Province, and was listed on July 13, 2021 [1] - The company's main business includes the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - Revenue composition: 73.19% from formulations, 25.22% from raw materials and intermediates, 1.52% from technical services, 0.06% from plant extracts and food, and 0.01% from other sources [1] Shareholder Information - In the second quarter, Invesco Great Wall Fund's "Invesco Great Wall Research Selected Stocks A" (000688) entered the top ten circulating shareholders of Warner Pharmaceutical, holding 1.2882 million shares, which is 0.98% of the circulating shares [2] - The fund has achieved a year-to-date return of 45.98% and a one-year return of 54.96%, ranking 463 out of 4220 and 372 out of 3857 in its category, respectively [2] Fund Manager Profile - The fund manager of Invesco Great Wall Research Selected Stocks A is Jiang Shan, who has been in the position for 4 years and 65 days [3] - The total asset size of the fund is 10.811 billion CNY, with the best return during Jiang's tenure being 181.78% and the worst being -16.09% [3]

Core Insights - Warner Pharmaceutical's stock increased by 5.11% to 60.88 CNY per share, with a trading volume of 207 million CNY and a turnover rate of 2.68%, resulting in a total market capitalization of 7.995 billion CNY [1] Company Overview - Hunan Warner Pharmaceutical Co., Ltd. is located in Changsha, Hunan Province, and was established on April 30, 2001, with its listing date on July 13, 2021 [1] - The company's main business includes the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - Revenue composition: Formulations account for 73.19%, raw materials and intermediates 25.22%, technical services 1.52%, plant extracts and food 0.06%, and others 0.01% [1] Shareholder Insights - Anxin Fund's Anxin Medical Health Stock A (010709) is among the top ten circulating shareholders of Warner Pharmaceutical, having increased its holdings by 504,400 shares in Q2, totaling 1,229,400 shares, which represents 0.94% of the circulating shares [2] - The estimated floating profit from this investment is approximately 3.639 million CNY [2] Fund Performance - Anxin Medical Health Stock A (010709) has a total asset size of 444 million CNY and has achieved a year-to-date return of 78.02%, ranking 57 out of 4,222 in its category [2] - Over the past year, the fund has returned 98.91%, ranking 578 out of 3,804, and since inception, it has achieved a return of 69.99% [2] Fund Manager Insights - The fund manager of Anxin Medical Health Stock A is Chi Chenshen, who has been in the position for 4 years and 251 days, with a total asset size of 946 million CNY [3] - The best fund return during his tenure is 72.35%, while the worst return is 68.37% [3] Fund Holdings - Anxin Medical Health Stock A (010709) has Warner Pharmaceutical as its sixth-largest holding, with 1,229,400 shares, accounting for 5.37% of the fund's net value [4] - The estimated floating profit from this position is also approximately 3.639 million CNY [4]

Group 1 - Warner Pharmaceutical's stock increased by 5.02%, reaching 53.93 CNY per share, with a trading volume of 199 million CNY and a turnover rate of 2.88%, resulting in a total market capitalization of 7.082 billion CNY [1] - The company, founded on April 30, 2001, and listed on July 13, 2021, is based in Changsha, Hunan Province, and specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - The revenue composition of Warner Pharmaceutical includes 74.47% from formulations, 24.46% from raw materials and intermediates, 0.99% from other sources, and 0.08% from plant extracts and food [1] Group 2 - Jinxin Fund holds a significant position in Warner Pharmaceutical, with its Jin Xin Value Selected Mixed A Fund (005117) owning 41,000 shares, accounting for 4.25% of the fund's net value, making it the seventh-largest holding [2] - The Jin Xin Value Selected Mixed A Fund has achieved a year-to-date return of 70.97%, ranking 212 out of 8,254 in its category, and a one-year return of 112.38%, ranking 252 out of 8,037 [2] - The fund managers, Liu Shang, Zhao Haoran, and Tan Zhiwei, have varying tenures and performance records, with Zhao Haoran achieving the best return of 49.65% during his tenure [2]

Group 1 - The stock price of TianKang is reported at 34.36 yuan, down by 1.09 yuan, a decrease of 3.07% from the previous trading day [1] - During the trading session, the stock reached a high of 35.35 yuan and a low of 34.35 yuan, with a trading volume of 56,956 hands and a transaction amount of 198 million yuan [1] - TianKang's main business includes the research, production, and sales of pharmaceutical products, covering chemical drug formulations, traditional Chinese medicine formulations, and raw materials [1] Group 2 - The company is committed to providing high-quality pharmaceutical products and services to patients [1] - Public information indicates that a pension fund entered the top ten circulating shareholders of TianKang in the second quarter, with an additional holding value exceeding 100 million yuan [1] - Data shows that on August 26, TianKang experienced a net outflow of 35.95 million yuan in main funds, with a net outflow of 36.94 million yuan over the past five days [1]